Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Smith

Showing results (11-20 of 189) with videos related to

Pageof 19
Sort By:
The Medical Journal of Australia|February 21, 2007
The doctor's dilemmaDavid E Smith
Journal of Psychoactive Drugs|January 13, 2016
Marijuana: A Fifty-Year Personal Addiction Medicine PerspectiveDavid E Smith
The Virtual Mentor : VM|November 10, 2012
The evolution of addiction medicine as a medical specialtyDavid E Smith
Journal of Psychoactive Drugs|January 23, 2016
Marijuana 2015: The More Things ChangeDavid E Smith, Steve Heilig
Biochemical Pharmacology|March 17, 2016
Species differences in the pharmacokinetics of cefadroxil as determined in wildtype and humanized PepT1 miceYongjun Hu, David E Smith
Journal of Psychoactive Drugs|November 19, 2015
The New Designer Drug Wave: A Clinical, Toxicological, and Legal AnalysisRyan Abbott, David E Smith
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 30, 2018
In Silico Prediction of the Absorption and Disposition of Cefadroxil in Humans using an Intestinal Permeability Method Scaled from Humanized <i>PepT1</i> MiceYongjun Hu, David E Smith
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 25, 2012
Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout miceBei Yang, David E Smith
Pharmaceutical Research|August 4, 2017
In Silico Absorption Analysis of Valacyclovir in Wildtype and Pept1 Knockout Mice Following Oral Dose EscalationBei Yang, David E Smith
Molecular Pharmaceutics|December 25, 2012
Impact of intestinal PepT1 on the kinetics and dynamics of N-formyl-methionyl-leucyl-phenylalanine, a bacterially-produced chemotactic peptideShu-Pei Wu, David E Smith
Pageof 19

Showing results (11-20 of 189) with videos related to

Sort By:
Pageof 19
The Medical Journal of Australia|February 21, 2007
The doctor's dilemmaDavid E Smith
Journal of Psychoactive Drugs|January 13, 2016
Marijuana: A Fifty-Year Personal Addiction Medicine PerspectiveDavid E Smith
The Virtual Mentor : VM|November 10, 2012
The evolution of addiction medicine as a medical specialtyDavid E Smith
Journal of Psychoactive Drugs|January 23, 2016
Marijuana 2015: The More Things ChangeDavid E Smith, Steve Heilig
Biochemical Pharmacology|March 17, 2016
Species differences in the pharmacokinetics of cefadroxil as determined in wildtype and humanized PepT1 miceYongjun Hu, David E Smith
Journal of Psychoactive Drugs|November 19, 2015
The New Designer Drug Wave: A Clinical, Toxicological, and Legal AnalysisRyan Abbott, David E Smith
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 30, 2018
In Silico Prediction of the Absorption and Disposition of Cefadroxil in Humans using an Intestinal Permeability Method Scaled from Humanized <i>PepT1</i> MiceYongjun Hu, David E Smith
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 25, 2012
Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout miceBei Yang, David E Smith
Pharmaceutical Research|August 4, 2017
In Silico Absorption Analysis of Valacyclovir in Wildtype and Pept1 Knockout Mice Following Oral Dose EscalationBei Yang, David E Smith
Molecular Pharmaceutics|December 25, 2012
Impact of intestinal PepT1 on the kinetics and dynamics of N-formyl-methionyl-leucyl-phenylalanine, a bacterially-produced chemotactic peptideShu-Pei Wu, David E Smith
Pageof 19